Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Trabectedin (Yondelis) received FDA approval for liposacoma and leiomyosarcoma, while the breast cancer agent eribulin (Halaven) is being studied in soft tissue sarcoma.

An agent being investigated in an ongoing phase III trial is olaratumab in combination with doxorubicin in advanced soft tissue sarcoma, which has demonstrated promising early-phase data. Olaratumab is a novel agent that could potentially be one of the first new drugs to add benefit to doxorubicin, which has been a standard treatment for several years.

View more from the 2015 CFS Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Sarcomas

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

PER® Chemotherapy Foundation Symposium (CFS)

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.


Dr. Philip on Olaratumab for Soft Tissue Sarcoma